MedPath

University of Virginia

University of Virginia logo
🇺🇸United States
Ownership
Private
Established
1819-01-01
Employees
10K
Market Cap
-
Website
http://www.virginia.edu

Clinical Trials

634

Active:29
Completed:294

Trial Phases

6 Phases

Early Phase 1:32
Phase 1:53
Phase 2:62
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (508 trials with phase data)• Click on a phase to view related trials

Not Applicable
312 (61.4%)
Phase 2
62 (12.2%)
Phase 1
53 (10.4%)
Early Phase 1
32 (6.3%)
Phase 4
26 (5.1%)
Phase 3
23 (4.5%)

Validation of a Portable Ankle Arthrometer

Not yet recruiting
Conditions
Chronic Ankle Instability, CAI
Ankle Sprain
Healthy
First Posted Date
2025-09-09
Last Posted Date
2025-09-09
Lead Sponsor
University of Virginia
Target Recruit Count
62
Registration Number
NCT07163897
Locations
🇺🇸

UVA Department of Student Health and Wellness, Charlottesville, Virginia, United States

A Preliminary Evaluation of Digital Behavioral Interventions

Not Applicable
Recruiting
Conditions
Mental Health Issue
Breast Cancer
First Posted Date
2025-09-08
Last Posted Date
2025-09-09
Lead Sponsor
University of Virginia
Target Recruit Count
120
Registration Number
NCT07160439
Locations
🇺🇸

University of Virginia, Charlottesville, Virginia, United States

Effect of Local Anesthetic Concentration on Rebound Pain: A Randomized Control Study

Not Applicable
Not yet recruiting
Conditions
Rebound Pain
Shoulder Arthroplasty
Interscalene Block
Interventions
First Posted Date
2025-08-28
Last Posted Date
2025-08-28
Lead Sponsor
University of Virginia
Target Recruit Count
168
Registration Number
NCT07146685
Locations
🇺🇸

UVA Health, Charlottesville, Virginia, United States

Interaction Between Inorganic Nitrate Supplementation and Metformin in Individuals With Prediabetes

Not Applicable
Not yet recruiting
Conditions
Males
Prediabetes
Females
Sedentary
Metformin
First Posted Date
2025-08-20
Last Posted Date
2025-08-26
Lead Sponsor
University of Virginia
Target Recruit Count
24
Registration Number
NCT07131384

The Effects of Vitamin C on Acute-Exercise in Postmenopausal Females

Not Applicable
Not yet recruiting
Conditions
Females
Males
Menopause
Sedentary
Healthy Participants
First Posted Date
2025-08-07
Last Posted Date
2025-08-07
Lead Sponsor
University of Virginia
Target Recruit Count
30
Registration Number
NCT07109115
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 127
  • Next

News

Virginia Approves Incentive Packages for AstraZeneca and Eli Lilly Manufacturing Plants

Virginia lawmakers unanimously approved economic development packages worth over $10 million each for AstraZeneca's multibillion-dollar manufacturing plant in Albemarle County and Eli Lilly's facility in Goochland County.

UVA Launches First-of-Its-Kind Psilocybin Trial for Prolonged Grief Disorder

The University of Virginia has initiated a groundbreaking clinical trial testing a single 25-milligram dose of psilocybin to treat prolonged grief disorder, a clinically recognized condition affecting approximately 10% of mourning individuals.

University of Virginia Expands Manning Institute of Biotechnology with $66M Additional Contract

Skanska has secured an additional $66 million contract with the University of Virginia to construct the Paul and Diane Manning Institute of Biotechnology, bringing advanced translational research capabilities to the Commonwealth.

Ascidian Therapeutics Advances RNA Exon Editing Platform with Key Leadership Appointments and Clinical Progress

Ascidian Therapeutics has assembled a distinguished Scientific Advisory Board featuring globally recognized RNA biology experts to guide its RNA exon editing platform development.

UVA Launches $30M Trial to Test Ketamine for Life-Threatening Seizures

The University of Virginia has secured a $9.3 million NIH grant as initial funding for a $30 million clinical trial investigating ketamine's potential in treating status epilepticus, a life-threatening seizure condition.

UVA Initiates Clinical Trial of AI-Enhanced Automated Insulin Delivery System for Type 1 Diabetes

• The University of Virginia is launching a clinical trial to evaluate an AI-powered "Bolus Priming System with Reinforcement Learning" (BPS_RL) for automated insulin delivery in Type 1 diabetes patients. • The three-week trial will involve 16 adult participants testing the enhanced system, which integrates with existing AIDANET technology including a phone app, Dexcom glucose monitor, and Tandem insulin pump. • The innovative system aims to improve blood sugar control during meals and overnight without requiring user input, potentially reducing the burden of diabetes management.

Cannabinoids Show Promise in Managing Peripheral Neuropathy Symptoms

A systematic review of 14 clinical trials indicates that cannabis-based medicines may effectively treat peripheral neuropathy by reducing neuropathic pain.

Daratumumab/Lenalidomide Combo Improves MRD Negativity in Myeloma Maintenance

A post hoc analysis of the AURIGA trial reveals that adding daratumumab to lenalidomide enhances minimal residual disease (MRD)-negativity conversion rates in multiple myeloma patients post-transplant.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.